Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSara Medek
About this trial
This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.
Eligibility criteria
Qualifiers
Patients must have histologically or cytologically confirmed history of squamous cell carcinoma of the oropharynx (OPSCC) planned for definitive chemoradiation.
Squamous cell carcinoma of the oropharynx (OPSCC) must be confirmed to be p16 positive based on immunohistochemical staining.
OPSCC must be clinical stage T1-4N1-3M0 or T3-T4N0M0 as per AJCC volume 8.
Patients must have measurable disease based on PET/CT imaging completed within 45 days +/- 1 week from date of eligibility confirmation.
Disqualifiers
1. Patients with metastatic or recurrent disease.
Trial design
Treatments tested in this trial
- Cisplatin
- Radiotherapy
Treatment groups
31 Participants
are divided into 1 treatment groupSponsors and collaborators
Sara Medek
Lead sponsor
University of Cincinnati
Sponsor institution
Source ClinicalTrials.gov